NASDAQ:IDYA

IDEAYA Biosciences Q1 2025 Earnings Results & Report

IDEAYA Biosciences logo
$27.40 -2.96 (-9.75%)
Closing price 04:00 PM Eastern
Extended Trading
$26.70 -0.70 (-2.55%)
As of 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEAYA Biosciences missed analyst earnings expectations in its Q1 2025 results, released May 6, 2025. The company reported EPS of -$0.82 versus the -$0.75 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
6:00 AM ET

IDEAYA Biosciences EPS Results

Actual EPS
-$0.82
Consensus EPS
-$0.75
Beat/Miss
Missed by -$0.07
One Year Ago EPS
-$0.53
EPS Beat Rate
2 of last 8 quarters

IDEAYA Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

IDEAYA Biosciences Q1 2025 Earnings FAQ

IDEAYA Biosciences (NASDAQ:IDYA) reported earnings of -$0.82 per share for Q1 2025, missing the consensus estimate of -$0.75. The report was announced on Tuesday, May 6, 2025.

IDEAYA Biosciences Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
IDEAYA Biosciences (IDYA) vs. The Competition Financial Survey
Transcript : IDEAYA Biosciences, Inc. - Special Call
See More IDEAYA Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IDEAYA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IDEAYA Biosciences and other key companies, straight to your email.

About IDEAYA Biosciences

IDEAYA Biosciences (NASDAQ:IDYA) is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets.

The company’s investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations. These candidates remain under clinical investigation; IDEAYA does not sell approved medicines.

Founded in 2015 and headquartered in South San Francisco, California, IDEAYA conducts research and advances clinical development programs, including through collaborations with other biotechnology and pharmaceutical companies. Yujiro S. Hata is the company’s chief executive officer.

View IDEAYA Biosciences Profile